Opinion

Video

Adherence in Psoriasis Care: Barriers, Solutions, and the Road Ahead

A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable differences in treatment patterns, discontinuation rates, persistence, and adherence among psoriasis patients treated with different biologics including tildrakizumab, risankizumab, guselkumab, and ustekinumab, with implications for clinical decision-making based on early versus late disease onset and prior biologic exposure.

  • What challenges do you anticipate in maintaining high treatment adherence rates for psoriasis therapies?
  • With increasing availability of targeted biologic therapies, how do you anticipate treatment strategies for psoriasis will continue to evolve?
Related Videos
Raj Chovatiya, MD, PhD, MSCI.
Galen Shearn-Nance, BS, and Johnie Rose, MD, PhD
4 experts are featured in this series.
4 experts are featured in this series.
Galen Shearn-Nance, BS
4 experts are featured in this series.
5 experts are featured in this series
Related Content
Patient taking survey | Image Credit: terovesalainen - stock.adobe.com
April 15th 2025

EHR-Based Symptom Inventory Shows Potential for Ovarian Cancer Monitoring

Brooke McCormick
The electronic health record (EHR)–based symptom inventory identified symptom prevalence and associated comorbidities, but no ovarian cancers were diagnosed during the study period.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
Hives, allergy. | Image Credit: Tanapat Lek,jew - stock.adobe.com
April 15th 2025

Significant Disease Burden and Management Issues in Chronic Spontaneous Urticaria

Cameron Santoro
Patients with chronic spontaneous urticaria experienced a long delay in diagnosis, a substantial impact on their quality of life, and often received inadequate treatment, highlighting the need for better management and understanding of the condition.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
Person holding microplastics | Image Credit: Pcess609 - stock.adobe.com
April 11th 2025

Health Risks of Microplastics Highlighted at Recent Medical Conferences

Brooke McCormick
Experts at leading health care conferences last month called for further research into the health effects of microplastics and prompted immediate action to limit exposure.
None of the eteplirsen-treated patients reached an LVEF below 50%, compared with 22.1% of patients in the control group. | Image credit: inthasone - stock.adobe.com
April 11th 2025

Eteplirsen Treatment Linked to Slower Cardiac Decline in DMD

Rose McNulty
None of the eteplirsen-treated patients reached a left ventricular ejection fraction below 50% compared with 22.1% of patients in the control group.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo